The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study.
 
Geoffrey Chong
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene (Inst); Takeda (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dizal Pharma (Inst); Dizal Pharma (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Isofol Medical (Inst); Merck Serono (Inst); MorphoSys (Inst); Pharmacyclics (Inst); Regeneron (Inst); Seagen (Inst)
 
Jodie Palmer
Stock and Other Ownership Interests - Avecho
 
Allison Barraclough
Honoraria - BeiGene; Gilead Sciences; Novartis; Roche
Travel, Accommodations, Expenses - Roche
 
Leonid Churilov
No Relationships to Disclose
 
Colm Keane
Honoraria - Beigene; Gilead Sciences; MSD Oncology; Roche
Research Funding - BeiGene; MSD Oncology
 
Sze Ting Lee
No Relationships to Disclose
 
Denise Lee
Honoraria - Roche
Consulting or Advisory Role - Gilead Sciences
 
Sumita Ratnasingam
No Relationships to Disclose
 
Charmaine Smith
No Relationships to Disclose
 
Eliza Anne Hawkes
Consulting or Advisory Role - AstraZeneca; BeiGene (Inst); Bristol Myers Squibb (Inst); Gilead Sciences (Inst); Janssen Oncology; Link healthcare (Inst); Merck Sharpe & Dohme (Inst); Novartis (Inst); Regeneron (Inst)
Speakers' Bureau - Abbvie (Inst); Regeneron; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gilead Sciences (Inst); Janssen-Cilag (Inst); Merck KGaA (Inst); Mundipharma (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca